In light of these preclinical results, standard and specialized neurologic and audiologic safety assessments and adjudication of events were conducted across the ALLEGRO program.25 Clinical data from the integrated safety analysis, including adjudicated events deemed possible neurologic or audiologic events of interest, showed no evidence of neurotoxicity with ritlecitinib treatment.25 Most AEs associated with neurologic events of interest such as dysesthesia, hyperesthesia, hypoesthesia, and paresthesia were mild in severity, considered by investigators to be unrelated to treatment, and resolved spontaneously.25 In a placebo-controlled phase 2a clinical safety study specifically evaluating potential neurologic/neuroaudiologic effects of ritlecitinib in adults with AA using BAEP assessments and intraepidermal axon histology, no notable effects were observed on nerve fiber counts, intraepidermal axon inflammation, or integrity of the human brainstem auditory pathway as assessed by BAEP.25 These data support that the dog finding of axonal dystrophy is not clinically relevant in humans.25 Laboratory assessments Ritlecitinib was associated with early, dose-dependent decreases in lymphocyte counts
Active or passive exposure to tobacco smoking and allergic rhinitis, allergic dermatitis, and food allergy in adults and children: a systematic review and meta-analysis
Basing clinical decisions on 6-TGN levels alone can overlook NUDT15-deficient patients who are prone to thiopurine-induced myelosuppression
That is the exact concern this stack is built around
The analysis showed modules containing pathogenicity-specific lncRNAs with various enrichments
The lower total BMD and lower trabecular parameters in active/former smokers may reflect the data of Lee et al., were a higher fracture-risk after stroke in smoking patients was shown
